About AIER News Social Responsibility
Professor Peng Xiaoyan, a renowned specialist in fundus and difficult eye diseases, joins Aier Hospital Group Caring for veterans' eye health, "Warmth for veterans - Guarding the light" public welfare action launched in Beijing Accelerating the accumulation of data assets and popularizing high-level ophthalmic medical services with artificial intelligence - AIER continues to work with the Chinese Academy of Sciences on digital ophthalmology development strategies The first new generation of astigmatism-correcting cataract surgery in China was successfully completed at AIER Prof. Zheng Wang has been invited to become a Fellow of the World College of Refractive Surgery and Vision Science (WCRS)! Ministry of Science and Technology's key research and development project lands in AIER for the first time, focusing on myopia prevention and control Talent planning - AIER launched the "Beidou talent plan", to build a global ophthalmic talent ecosystem The alliance between giants - AIER and China Eye Valley shows a sound momentum of all-round and in-depth eye health development AIER will donate 20 billion yuan in the next ten years to build a sustainable eye healthcare ecosystem Living up to our responsibility！ AIER received the Top 500 Chinese Brand Value Award with the "Huapu Award" for three consecutive years The research results of Prof. Jiansu Chen and Shibo Tang’s team from AIER were published in the International journal (impact factor: 10.633) Professor Fengyuan Sun, an oculoplastic & orbit disease expert in China, joined AIER to build the "Last Stop" for the diagnosis and treatment of intractable diseases 2021 AIER EYE HOSPITAL GROUP CO., LTD. Social Responsibility Report Prof. Weizhong Lan from AIER was invited to WHO-ITU Be He@lthy, Be Mobile toolkit for the myopia launch meeting AIER Eye Hospital Group donates 2 million yuan to Suzhou fight against the pandemic — Caring donation before Suzhou AIER Eye Hospital officially open AIER Eye Hospital Group received “The Red Cross Award of China” Prof. ZhiKuan Yang of AIER was elected president of the second council of Hunan Optometric Association Prof. Shibo Tang from AIER received the "China Industry-University-Research Collaboration Innovation and Promotion Award" AIER receives “Best Information Disclosure Award”by the Excellence IR School-enterprise cooperation making new progress by providing opportunities and platforms for talents to stand out - AIER and Henan University agreed to establish a strategic partnership AIER Clinic of Myopia Prevention for Teenagers: " 5P Model for Myopic Prevention" 6 billion RMB! A new university in Changsha - AIER International Medical College project signed Strategic Alliance Formed Between AIER and Sichuan University Protecting children and teenager’s eye health, "Red Cross Eye Protection Program " officially launched in Beijing Speech from Mr. Bang Chen on the China Charity Culture Forum: National consciousness and global mindset from AIER AIER Eye Hospital Group officially has a seat on the board of the World Association of Eye Hospital AIER won the "China Charity Awards" for two consecutive years Professor Jiansu Chen’s team from AIER researched the human corneal stromal cells from SMILE surgery The graduation ceremony of AIER School of Ophthalmology, CSU was held grandly, nearly 200 talents were trained in 6 years. The Rescue: AIER donates 5 million yuan to support disaster relief in Henan province. Malaysian Royal Datuk: Such a good doctor and team should be known to the world! From “poverty-alleviation” to “rural revitalization” AIER Is on the way to making brighter China mission possible Mr. Bang Chen, Chairman of AIER Eye Hospital Group, has been honored as "Excellent Builder of Socialism with Chinese Characteristics" ​Tianjin University AIER Eye Hospital opening ceremony was founded AIER and Singapore Eye Institute jointly tackle the key issues to build a whole chain of myopia research system Research team was led by principal of Jinan University, negotiating a tie-up cooperation with AIER. Optometry talent training accelerated; strategic alliance formed between Tianjin Vocational Institute & AIER Alliance between giants - AIER and the Chinese Academy of Sciences launch the STS "Smart Eye Care" project The number of SCI papers of AIER School of Ophthalmology CSU ranks among the top 20 in China Prospering in the pandemic : 2020's top 100 companies - AIER The awarding ceremony of "National Post-doctoral Research Workstation" of AIER was held in Changsha In the new round of national science & technology innovation platform construction, AIER is listed as the key cultivation object in Hunan Lan Wu, Deputy Secretary of the CPC Hunan Provincial Committee: Support AIER to grow bigger, benefit the eye health industry with more efforts. AIER is named as "The Most Influential 30 Listed Companies in 2020" Strategic Alliance Formed Between Anhui Medical University & AIER to Build a First-class Platform for Ophthalmology in Central China AIER Receives "Huapu Award" and "Anti-Epidemic Tribute Brand Enterprise" at China Brand Festival 2020 AIER Supports CSU with Double First-Class University Project, Rewarding All Medical Staff in Frontline Strategic Alliance Formed Between Jinan University & AIER to Build a First-class Platform for Ophthalmology Annual report of AIER Eye Hospital Group in 2019 Salute to all cornea donors Report of AIER's Fighting against COVID-19 Mourning to Doctor Li Wenliang AIER is Selected into CSI 100 Index International Retina Summit Forum 2019 Grandly opened, AIER Released the Big Data Report on Fundus Disease in Chinease Population Allied AIER & Novartis Establish an Innovative Mode for Chinese Eye Disease Diagnosis & Treatment Five AIER Eye Hospitals Certified by GCP AIER Selected as "Top 20 Competitive Chinese Pharmaceutical Listed Companies of 2019" Together We are Stronger - AIER & Alcon Global Strategic Cooperation Conference Held at Alcon Headquarter AIER Wins Bid for the 19th International Myopia Conference AIER: Exploring Innovation-Integrated Development Model, Sharing Global Vision AIER Acquires ISEC Group, One Big Step in the Belt&Road AIER's Talent Strategies for the Next Decade are Officially Released Led by AIER, the first National Hereditary Eye Diseases Committee is founded Huawei & Talkweb Join AIER to Build an Ophthalmic Medical Industry Ecosystem Enhance Innovation Ability, AIER Create a New Translation Model AIER Opens Up A New Era of Personalizing Myopia Prevent and Control Talent Strategy Helps "100-Year AIER" Dream AIER Eye Hospital Group was awarded the highest government award for charity - China Charity Award IOC - AIER Work Together for Training International High-end Ophthalmology Talents "Shigatse Charity Brightness Action" Helped Nearly 50 Tibetans Regain Their Vision AIER Eye Hospital Group Europe Holding Company Clinica Baviera Successfully Listed in Spain Focus on the New Trend of Global Refractive Surgery Grand opening of 2018 International Refractive Surgery Symposium AIER Eye Hospital Group Releases New Laser Surgery Technology-Smart 3D Prolonged Mobile Phone Use Accelerates the Incidence of Multiple Eye Diseases The Second Phase of "Lancang-Mekong Brightness Action" was Launched in Cambodia China Will Take the Lead to Solve the "Century Problem" of the Pathogenesis of Individual's Myopia AIER Eye Hospital Group is awarded China's Top 10 Investor-Respected Listed Company Aagain! Experts From AIER Have Gotten A Lot of Traction at Retina China 2018 Cooperating with Singapore National Eye Center and Singapore Eye Research Institute "China Bethune" is Famous Among Vietnamese AIER Institute for Corneal Disease Established, Dedicate to Improve China’s Medical Level for Corneal Diseases AIER Was Invited To Attend The Annual Conference Of The International Children's Vision Health Program Precision Anti-Poverty Operation: for 2000 Impoverished Patients in Xiangxi Breaking News: AIER Won the "2017 Excellent Public Welfare Project" Myopia Prevention and Control-Strategy & Perspective - Boao Forum for Vision 2017 2017 International Retina Summit (IRS) Closing AIER Reaches The Target of 200 Hospitals in Mainland China Earlier AIER’s Experts Won Awards at the 35th Congress of ESCRS Chinese Eye Hospital Group Completes Acquisition of Spanish Clinica Baviera "Visual Health Precision Poverty Alleviation Action" For Half a Million Impoverish Patients AIER Eye Hospital Group Acquired Clínica Baviera AIER Joints INTEL to Create Artificial Intelligence Eye Disease Identification Solutions Ieyecloud Private Eye Doctors Providing Signed Patients With Online Eye Health Services Big Data Technology, New Direction for Clinical Prevention and Control of Myopia AIER Eye Hospital Group Acquired AW Healthcare Management
The research results of Prof. Jiansu Chen and Shibo Tang’s team from AIER were published in the International journal (impact factor: 10.633)

2022-08-08 00:00:00

图片.png


The research results of Prof. Jiansu Chen, Prof. Shibo Tang and associate researcher Zekai Cui from AIER Eye Institute were published in Acta Biomaterialia (recent impact factor: 10.633), an international journal in the field of biomedicine



With the advent of the era of the “Digital Screen”, a growing number of high-tech products, make more people focus their eyes and attention on screens for long periods, resulting in excessive eye fatigue，dry sensation, foreign body sensation, burning sensation, red eye itching, blurred vision, pain, photophobia tears, and serious corneal damage with even visual impairment. Corneal nerve damage is one of the factors causing these symptoms. Neurotrophic keratitis and diabetes can also cause corneal nerve damage, resulting corneal discomfort. However, the specific molecular mechanism of corneal nerve injury repair is not fully understood.



Based on their earlier stage achievements, Prof. Jiansu Chen, Prof. Shibo Tang and associate researcher Zekai Cui from AIER Eye Institute found that the human corneal stromal cells (referred to as hCSCs) cut from the SMILE surgery can be reused, turning waste into treasure (the results were published in <Journal of Cellular and Molecular Medicine>, and an in vitro corneal stromal and nerve co-culture 3D model was designed and constructed this time, the results were recently published in the journal Acta Biomaterialia.




It is understood that Acta Biomaterialia is the Top journal of the First District of the Chinese Academy of Sciences, with the latest impact factor of 10.633. It is an international journal in the biomedical field. The content of Acta Biomaterialia papers is also regarded as a certain industry indicator, which is highly recognized by the industry.

 

In this model, the team found that hCSCs and nerves interact. The nerve prevents hCSCs from apoptosis in the serum withdrawal medium, leading to the growth of nerve bundles. The small molecule LM22B-10 was also screened out by protein microarray and transcriptomic deep detection, which has the mechanism of promoting nerve regeneration and is stable and not easy to degrade. The construction of the dorsal root ganglion-corneal stromal cell co-culture 3D model has created a good platform and tool to explore the mechanism of corneal nerve regeneration and verification of drug effects.


The cornea has a high nerve density and is one of the most sensitive tissues In the human body. Studies have shown that the density of pain receptors in the cornea is 300 to 600 times that of the skin,  20 to 40 times that of the dental pulp, and any damage to the structure of the cornea can cause extreme pain to the patient. We know a healthy cornea has no blood vessels. oxygen and nutrients are provided to the corneal cells through tears and aqueous humour, and the corneal nerves also provide some nutrients, which play a crucial role in maintaining corneal homeostasis.



Based on this, after administering LM22B-10 eye drops to regular and diabetic mice with corneal wounding, the team found that LM22B-10 significantly improves the healing speed of the corneal epithelium, corneal sensitivity, and corneal nerve density. After passing preclinical trials and clinical trials, it can relieve and treat neurotrophic keratitis, diabetic keratitis and other corneal nerve injury-related diseases or symptoms. In general, compared with traditional nerve growth factors, LM22B-10 has the characteristics and advantages of high efficiency, easy degradation, low pain and low cost. It has great potential in nerve repair and corneal injury healing and is expected to become a new clinical treatment drug for corneal diseases.



“LM22B-10 has shown promising results in the treatment of corneal epithelial and corneal nerve injuries. Compared with other neurotrophins, LM22B-10 does not trigger the activation of pain receptors. Moreover, the small molecules are not as easily degraded as peptides, so the cost would be much lower. In the future, it is expected to become one of the specific drugs for ocular surface injury and nerve injury after preclinical trials and clinical trials.” On behalf of the team, Prof. Jiansu Chen said, “AIER Eye Hospital Group (referred to as “AIER”) is China's leading ophthalmology hospital group that covers Asia, Europe, and North America with a total number of more than 700 specialized eye hospitals and centres around the world, which has significant advantages for conducting multi-centre and large-sample studies.

We look forward to our colleagues making more contributions to the cause of human eye health by utilizing advanced stem cell, tissue engineering and eye regenerative medicine technologies in this international fertile ground.”